Compare Illumina, Inc. (ILMN) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Illumina, Inc. trades at $184.68 (market cap $27.94B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.47. Which is the better fit depends on your goals.
| ILMN | VEA | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | — |
52-Week High | $194.33 | $72.39 |
52-Week Low | $91.00 | $56.02 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VEA trades at $69.23, down 0.67% with a bearish technical signal from moving averages. The ETF maintains strong institutional interest with recent purchases by Greenwood Gearhart and Bessemer Group. VEA offers exposure to developed international markets with a low 0.03% expense ratio and $304 billion in assets under management, providing diversification benefits amid current market conditions.
VEA presents a compelling international diversification opportunity with cost efficiency and solid institutional backing. Key risks include developed market monetary policy shifts and currency fluctuations. The ETF's valuation discount to US markets and consistent institutional accumulation support long-term positioning despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
